CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

CADTH Canadian Drug Expert Committee recommendation. indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Guselkumab (Tremfya -- Janssen Inc.) :

Show other versions (2)

The CADTH Canadian Drug Expert Committee (CDEC) recommends that guselkumab be reimbursed for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, with the following criteria and condition. Reimburse in a manner similar to other biologics fo...

Full description

Saved in:
Bibliographic Details
Online Access: http://www.ncbi.nlm.nih.gov/books/NBK532985/
Full text
Corporate Author: CADTH Canadian Drug Expert Committee (Author)
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : CADTH, 2018
Edition:Version 1.0.
Series:Common drug review clinical review report.
Subjects:
Psoriasis > drug therapy.
Antibodies, Monoclonal > therapeutic use.
Antibodies, Monoclonal > economics.
Interleukin-23 Subunit p19 > therapeutic use.
Interleukin-23 Subunit p19 > economics.
Drug Costs.
Insurance, Health, Reimbursement.
Canada.

Internet

http://www.ncbi.nlm.nih.gov/books/NBK532985/
Full text

Similar Items